Risperidone prevents the development of supersensitivity, but not tolerance, to phencyclidine in rats treated with subacute phencyclidine

Kiyoyuki Kitaichi, Kiyofumi Yamada, Yukio Yoneda, Kiyokazu Ogita, Takaaki Hasegawa, Hiroshi Furukawa, Toshitaka Nabeshima

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We investigated whether risperidone, a 5-HT2/dopamine-D2 receptor antagonist, inhibits the development of tolerance and supersensitivity to PCP and whether subacute administration of PCP with risperidone affects the [3H]MK-801 binding in rat brain, in comparison with dopamine-D2 receptor antagonist haloperidol and 5-HT2 receptor antagonist ritanserin. In rats treated with PCP (10 mg/Kg, I.p.) for 14 days, PCP (10 mg/Kg, I.p.)-induced hyperlocomotion, rearing and sniffing were potentiated (supersensitivity), and head-weaving, head-twitch, backpedalling and turning were diminished (tolerance). The development of supersensitivity to PCP was blocked by oral co-administration of risperidone (2.4 mg/Kg, P.o.) and haloperidol (1.0 mg/Kg, P.o.) for 14 days, but not ritanserin (10 mg/Kg, P.o.) and risperidone (0.8 mg/Kg, P.o.), while no drugs prevented the development of tolerance to PCP. Both risperidone (2.4 mg/Kg, P.o.) and haloperidol (1.0 mg/kg, p.o.) also inhibited the cross-supersensitivity to methamphetamine (MAP; 2.5 mg/Kg, I.p.)-induced rearing in rats treated with PCP for 14 days. The profiles of [3H]MK-801 binding in discrete brain areas did not change after subacute administration of PCP alone or in combination with risperidone, haloperidol or ritanserin for 14 days. Therefore, it is suggested that subacute administration of PCP may cause functional changes in the dopaminergic neuronal transmission under conditions where the binding of [3H]MK-801 in discrete brain areas is unchanged, and that co-administration of risperidone may block these PCP-induced changes in neuronal function.

Original languageEnglish
Pages (from-to)531-543
Number of pages13
JournalLife Sciences
Volume56
Issue number7
DOIs
Publication statusPublished - 06-01-1995
Externally publishedYes

Fingerprint

Phencyclidine
Risperidone
Rats
Ritanserin
Haloperidol
Dizocilpine Maleate
Brain
Head
Serotonin 5-HT2 Receptor Antagonists
Methamphetamine
Oral Administration
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Kitaichi, Kiyoyuki ; Yamada, Kiyofumi ; Yoneda, Yukio ; Ogita, Kiyokazu ; Hasegawa, Takaaki ; Furukawa, Hiroshi ; Nabeshima, Toshitaka. / Risperidone prevents the development of supersensitivity, but not tolerance, to phencyclidine in rats treated with subacute phencyclidine. In: Life Sciences. 1995 ; Vol. 56, No. 7. pp. 531-543.
@article{a623e5eba6c6468e811a88f97b296714,
title = "Risperidone prevents the development of supersensitivity, but not tolerance, to phencyclidine in rats treated with subacute phencyclidine",
abstract = "We investigated whether risperidone, a 5-HT2/dopamine-D2 receptor antagonist, inhibits the development of tolerance and supersensitivity to PCP and whether subacute administration of PCP with risperidone affects the [3H]MK-801 binding in rat brain, in comparison with dopamine-D2 receptor antagonist haloperidol and 5-HT2 receptor antagonist ritanserin. In rats treated with PCP (10 mg/Kg, I.p.) for 14 days, PCP (10 mg/Kg, I.p.)-induced hyperlocomotion, rearing and sniffing were potentiated (supersensitivity), and head-weaving, head-twitch, backpedalling and turning were diminished (tolerance). The development of supersensitivity to PCP was blocked by oral co-administration of risperidone (2.4 mg/Kg, P.o.) and haloperidol (1.0 mg/Kg, P.o.) for 14 days, but not ritanserin (10 mg/Kg, P.o.) and risperidone (0.8 mg/Kg, P.o.), while no drugs prevented the development of tolerance to PCP. Both risperidone (2.4 mg/Kg, P.o.) and haloperidol (1.0 mg/kg, p.o.) also inhibited the cross-supersensitivity to methamphetamine (MAP; 2.5 mg/Kg, I.p.)-induced rearing in rats treated with PCP for 14 days. The profiles of [3H]MK-801 binding in discrete brain areas did not change after subacute administration of PCP alone or in combination with risperidone, haloperidol or ritanserin for 14 days. Therefore, it is suggested that subacute administration of PCP may cause functional changes in the dopaminergic neuronal transmission under conditions where the binding of [3H]MK-801 in discrete brain areas is unchanged, and that co-administration of risperidone may block these PCP-induced changes in neuronal function.",
author = "Kiyoyuki Kitaichi and Kiyofumi Yamada and Yukio Yoneda and Kiyokazu Ogita and Takaaki Hasegawa and Hiroshi Furukawa and Toshitaka Nabeshima",
year = "1995",
month = "1",
day = "6",
doi = "10.1016/0024-3205(94)00482-8",
language = "English",
volume = "56",
pages = "531--543",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "7",

}

Risperidone prevents the development of supersensitivity, but not tolerance, to phencyclidine in rats treated with subacute phencyclidine. / Kitaichi, Kiyoyuki; Yamada, Kiyofumi; Yoneda, Yukio; Ogita, Kiyokazu; Hasegawa, Takaaki; Furukawa, Hiroshi; Nabeshima, Toshitaka.

In: Life Sciences, Vol. 56, No. 7, 06.01.1995, p. 531-543.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risperidone prevents the development of supersensitivity, but not tolerance, to phencyclidine in rats treated with subacute phencyclidine

AU - Kitaichi, Kiyoyuki

AU - Yamada, Kiyofumi

AU - Yoneda, Yukio

AU - Ogita, Kiyokazu

AU - Hasegawa, Takaaki

AU - Furukawa, Hiroshi

AU - Nabeshima, Toshitaka

PY - 1995/1/6

Y1 - 1995/1/6

N2 - We investigated whether risperidone, a 5-HT2/dopamine-D2 receptor antagonist, inhibits the development of tolerance and supersensitivity to PCP and whether subacute administration of PCP with risperidone affects the [3H]MK-801 binding in rat brain, in comparison with dopamine-D2 receptor antagonist haloperidol and 5-HT2 receptor antagonist ritanserin. In rats treated with PCP (10 mg/Kg, I.p.) for 14 days, PCP (10 mg/Kg, I.p.)-induced hyperlocomotion, rearing and sniffing were potentiated (supersensitivity), and head-weaving, head-twitch, backpedalling and turning were diminished (tolerance). The development of supersensitivity to PCP was blocked by oral co-administration of risperidone (2.4 mg/Kg, P.o.) and haloperidol (1.0 mg/Kg, P.o.) for 14 days, but not ritanserin (10 mg/Kg, P.o.) and risperidone (0.8 mg/Kg, P.o.), while no drugs prevented the development of tolerance to PCP. Both risperidone (2.4 mg/Kg, P.o.) and haloperidol (1.0 mg/kg, p.o.) also inhibited the cross-supersensitivity to methamphetamine (MAP; 2.5 mg/Kg, I.p.)-induced rearing in rats treated with PCP for 14 days. The profiles of [3H]MK-801 binding in discrete brain areas did not change after subacute administration of PCP alone or in combination with risperidone, haloperidol or ritanserin for 14 days. Therefore, it is suggested that subacute administration of PCP may cause functional changes in the dopaminergic neuronal transmission under conditions where the binding of [3H]MK-801 in discrete brain areas is unchanged, and that co-administration of risperidone may block these PCP-induced changes in neuronal function.

AB - We investigated whether risperidone, a 5-HT2/dopamine-D2 receptor antagonist, inhibits the development of tolerance and supersensitivity to PCP and whether subacute administration of PCP with risperidone affects the [3H]MK-801 binding in rat brain, in comparison with dopamine-D2 receptor antagonist haloperidol and 5-HT2 receptor antagonist ritanserin. In rats treated with PCP (10 mg/Kg, I.p.) for 14 days, PCP (10 mg/Kg, I.p.)-induced hyperlocomotion, rearing and sniffing were potentiated (supersensitivity), and head-weaving, head-twitch, backpedalling and turning were diminished (tolerance). The development of supersensitivity to PCP was blocked by oral co-administration of risperidone (2.4 mg/Kg, P.o.) and haloperidol (1.0 mg/Kg, P.o.) for 14 days, but not ritanserin (10 mg/Kg, P.o.) and risperidone (0.8 mg/Kg, P.o.), while no drugs prevented the development of tolerance to PCP. Both risperidone (2.4 mg/Kg, P.o.) and haloperidol (1.0 mg/kg, p.o.) also inhibited the cross-supersensitivity to methamphetamine (MAP; 2.5 mg/Kg, I.p.)-induced rearing in rats treated with PCP for 14 days. The profiles of [3H]MK-801 binding in discrete brain areas did not change after subacute administration of PCP alone or in combination with risperidone, haloperidol or ritanserin for 14 days. Therefore, it is suggested that subacute administration of PCP may cause functional changes in the dopaminergic neuronal transmission under conditions where the binding of [3H]MK-801 in discrete brain areas is unchanged, and that co-administration of risperidone may block these PCP-induced changes in neuronal function.

UR - http://www.scopus.com/inward/record.url?scp=0028890939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028890939&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(94)00482-8

DO - 10.1016/0024-3205(94)00482-8

M3 - Article

VL - 56

SP - 531

EP - 543

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 7

ER -